Ferumoxytol
- Generic Name
- Ferumoxytol
- Brand Names
- Feraheme
- Drug Type
- Small Molecule
- Chemical Formula
- Fe3O4
- CAS Number
- 722492-56-0
- Unique Ingredient Identifier
- G6N3J05W84
- Background
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
...
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) .
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT03619850
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇵🇱Polish Mother's Memorial Hospital Research Institute, Łódź, Poland
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT03347617
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03325166
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03280277
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT03270059
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT03234309
In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Michael Iv
- Registration Number
- NCT03179449
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT03173066
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Ferumoxytol-enhanced Magnetic Resonance Imaging
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 185
- Registration Number
- NCT02954510
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT02857218
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.